Gene · 5892
Papers2,681
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 2,681
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Similarities and differences in gene expression profiles of BRCA1 methylated and mutated epithelial ovarian cancers. | Front Oncol | 2023 | 37854675 | PubTator, text mining | PubMed |
| The Largest Chinese Cohort Study Indicates Homologous Recombination Pathway Gene Mutations as Another Major Genetic Risk Factor for Colorectal Cancer with Heterogeneous Clinical Phenotypes. | Research (Wash D C) | 2023 | 37854294 | PubTator, text mining | PubMed |
| Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. | ESMO Open | 2023 | 37852034 | PubTator, text mining | PubMed |
| RAD51 paralogs synergize with RAD51 to protect reversed forks from cellular nucleases. | Nucleic Acids Res | 2023 | 37843130 | PubTator, text mining | PubMed |
| The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities. | Cancer Drug Resist | 2023 | 37842243 | PubTator, text mining | PubMed |
| Next-generation sequencing in dermatology. | Front Med (Lausanne) | 2023 | 37841001 | PubTator, text mining | PubMed |
| High PGAP3 expression is associated with lymph node metastasis and low CD8+T cell in patients with HER2+ breast cancer. | Pathol Res Pract | 2023 | 37839361 | PubTator, text mining | PubMed |
| New Facets of DNA Double Strand Break Repair: Radiation Dose as Key Determinant of HR versus c-NHEJ Engagement. | Int J Mol Sci | 2023 | 37834403 | PubTator, text mining | PubMed |
| RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC. | Int J Mol Sci | 2023 | 37833926 | PubTator, text mining | PubMed |
| ADP-ribosylation from molecular mechanisms to therapeutic implications. | Cell | 2023 | 37832523 | PubTator, text mining | PubMed |
| [BRCA-like breast cancer patients benefit from cisplatin plus veliparib-results from the S1416 phase II study]. | Strahlenther Onkol | 2023 | 37823898 | PubTator, text mining | PubMed |
| Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays. | NPJ Precis Oncol | 2023 | 37821580 | PubTator, text mining | PubMed |
| Male awareness of prostate cancer risk remains poor in relatives of women with germline variants in DNA-repair genes. | BJUI Compass | 2023 | 37818031 | PubTator, text mining | PubMed |
| RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis. | Oncol Lett | 2023 | 37809048 | PubTator, text mining | PubMed |
| RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma. | Cancer Cell Int | 2023 | 37798649 | PubTator, text mining | PubMed |
| Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity. | Oncotarget | 2023 | 37791908 | PubTator, text mining | PubMed |
| Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls. | Front Genet | 2023 | 37790698 | PubTator, text mining | PubMed |
| Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives. | Front Oncol | 2023 | 37781190 | PubTator, text mining | PubMed |
| Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010). | Clin Cancer Res | 2023 | 37773077 | PubTator, text mining | PubMed |
| A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177Lutetium-DOTA-octreotate radionuclide therapy. | Theranostics | 2023 | 37771787 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5892/papers?page=15